Literature DB >> 17111149

Retinal toxicity of triamcinolone's vehicle (benzyl alcohol): an electrophysiologic and electron microscopic study.

Tamer A Macky1, Dina Helmy, Nihal El Shazly.   

Abstract

PURPOSE: To assess retinal toxicity of the vehicle of triamcinolone, benzyl alcohol (BA), when injected into the vitreous cavity of rabbits.
METHODS: This prospective comparative experimental study included 24 pigmented rabbits assigned into two groups: group 1 (experimental, n = 12) received intravitreal 0.1 ml of BA, and group 2 (control, n = 12) received intravitreal 0.1 ml of balanced salt solution (BSS); all injections were done in the right eyes. Clinical examinations [slit lamp biomicroscopy, indirect ophthalmoloscopy, and three intraocular pressure (IOP) measurements] were done on both eyes before injection, at 1 and 3 h post injection, together with electroretinograms (ERGs) at 3 days, 1, 2, 4, and 6 weeks following injections. Three rabbits from each group were euthanased at 1, 2, 4, or 6 weeks and eyes were sent for light and electron microscopic examination for quantitative morphometric measurements.
RESULTS: The mean amplitudes of the a and b waves of the BA-injected eyes were 6.42 +/- 9.02 microv and 11.18 +/- 15.18 microv at 3 days, respectively, which were significantly reduced compared with the BSS-injected eyes (30.87 +/- 8.22 microv and 57.90 +/- 13.38 microv, respectively; P < 0.01 t-test) and the non-injected contralateral eyes (36.20 +/- 7.85 microv and 64.10 +/- 9.36 microv, respectively; P < 0.01 t-test). These ERG responses continued to be significantly reduced in the BA-injected eyes (P < 0.01 t-test) throughout the study period. The mean ganglion cell count was significantly reduced (P < 0.005 t-test) in the BA-injected eyes (8.42 +/- 2.4) compared with the BSS- and non-injected eyes (16.42 +/- 3.9 and 16.5 +/- 4.2, respectively). The mean thicknesses of the inner nuclear layer (INL) and outer nuclear layer (ONL) were significantly reduced (P < 0.005 t-test) in the BA-injected eyes (3.78 +/- 0.96 microm and 11.77 +/- 1.29 microm, respectively) compared with the BSS- (6.1 +/- 0.92 microm and 21.82 +/- 0.95 microm, respectively) and non-injected eyes (7.05 +/- 1.9 microm and 22.49 +/- 1.01 microm, respectively). Electron microscopy showed moderate to severe intracellular changes in the ganglion cell layer, INL, ONL, and photoreceptor layer at 6 weeks in BA-injected eyes, with no significant changes in BSS-injected eye. There was no significant rise in the IOP or clinical evidence of increased lens density during the study period in any of the eyes.
CONCLUSIONS: Triamcinolone acetonide's vehicle, BA, produced severe ERG and structural damage to the retina when injected intravitreally.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17111149     DOI: 10.1007/s00417-006-0459-3

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.535


  28 in total

1.  Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration.

Authors:  Jost B Jonas; Imren Akkoyun; Wido M Budde; Ingrid Kreissig; Robert F Degenring
Journal:  Arch Ophthalmol       Date:  2004-02

2.  Intravitreal triamcinolone for radiation-induced macular edema.

Authors:  Florian K P Sutter; Mark C Gillies
Journal:  Arch Ophthalmol       Date:  2003-10

3.  Intravitreal triamcinolone acetonide for exudative age related macular degeneration.

Authors:  J B Jonas; I Kreissig; P Hugger; G Sauder; S Panda-Jonas; R Degenring
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

4.  Safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema.

Authors:  Sofia Androudi; Erik Letko; Margherita Meniconi; Thekla Papadaki; Muna Ahmed; C Stephen Foster
Journal:  Ocul Immunol Inflamm       Date:  2005 Apr-Jun       Impact factor: 3.070

5.  Regression of neovascular iris vessels by intravitreal injection of crystalline cortisone.

Authors:  J B Jonas; J K Hayler; A Söfker; S Panda-Jonas
Journal:  J Glaucoma       Date:  2001-08       Impact factor: 2.503

6.  An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy.

Authors:  C S Yang; J A Khawly; D P Hainsworth; S N Chen; P Ashton; H Guo; G J Jaffe
Journal:  Arch Ophthalmol       Date:  1998-01

7.  Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy.

Authors:  J B Jonas; J K Hayler; S Panda-Jonas
Journal:  Br J Ophthalmol       Date:  2000-09       Impact factor: 4.638

8.  Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization.

Authors:  Richard F Spaide; John Sorenson; Leandro Maranan
Journal:  Ophthalmology       Date:  2005-02       Impact factor: 12.079

9.  Intravitreal triamcinolone acetonide in refractory pseudophakic cystoid macular edema: functional and anatomic results.

Authors:  F Boscia; C Furino; R Dammacco; P Ferreri; L Sborgia; C Sborgia
Journal:  Eur J Ophthalmol       Date:  2005 Jan-Feb       Impact factor: 2.597

10.  Intravitreal preservative-free triamcinolone acetonide for the treatment of macular oedema.

Authors:  S J Bakri; A Shah; N S Falk; P M Beer
Journal:  Eye (Lond)       Date:  2005-06       Impact factor: 3.775

View more
  7 in total

1.  Steroid differentiation: the safety profile of various steroids on retinal cells in vitro and their implications for clinical use (an American Ophthalmological Society thesis).

Authors:  Baruch D Kuppermann; Leandro Cabral Zacharias; M Cristina Kenney
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

2.  Injectable corticosteroid preparations: an embolic risk assessment by static and dynamic microscopic analysis.

Authors:  P J MacMahon; M J Shelly; D Scholz; S J Eustace; E C Kavanagh
Journal:  AJNR Am J Neuroradiol       Date:  2011-09-22       Impact factor: 3.825

3.  Comparisons of cone electroretinograms after indocyanine green-, brilliant blue G-, or triamcinolone acetonide-assisted macular hole surgery.

Authors:  Shigeki Machida; Yoshiharu Toba; Tomoharu Nishimura; Takayuki Ohzeki; Ken-ichi Murai; Daijiro Kurosaka
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-03-02       Impact factor: 3.117

4.  Subretinal injection of preservative-free triamcinolone acetonide and supernatant vehicle in rabbits: an electron microscopy study.

Authors:  Maurício Maia; Fernando Marcondes Penha; Michel Eid Farah; Eduardo Dib; André Príncipe; Acácio A S Lima Filho; Octaviano Magalhães; Edna Freymüller; Eduardo B Rodrigues
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-12-11       Impact factor: 3.117

Review 5.  Visualizing vitreous in vitrectomy by triamcinolone.

Authors:  Taiji Sakamoto; Tatsuro Ishibashi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-06-20       Impact factor: 3.117

6.  Pharmacokinetics and retinal toxicity of various doses of intravitreal triamcinolone acetonide in rabbits.

Authors:  You-Fan Ye; Yong-Feng Gao; Hua-Tao Xie; Hai-Jun Wang
Journal:  Mol Vis       Date:  2014-05-13       Impact factor: 2.367

7.  Long-Term Outcomes of Macular Hole Repair with Triamcinolone Acetonide Visualization.

Authors:  Josh Wallsh; Masumi G Asahi; Ron Gallemore
Journal:  Clin Ophthalmol       Date:  2021-04-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.